Targeted Therapy for NSCLC: Antibody-Drug Conjugates (ADCs)

Availability

On-Demand

3 Courses

Cost

$0.00

This video series provides an overview of the adoption of antibody-drug conjugates (ADCs) to treat non-small cell lung cancer (NSCLC). The series will cover:

Targeted Therapy for NSCLC: Toxicity Profile of ADCs
ADCs Targeting TROP2 in NSCLC: Overview and Recent Data
ADCs for NSCLC: HER2 and HER3

Learning Objectives:

Upon completion of this activity, participants should be better able to:

Address barriers to the awareness, preparedness, adoption, and potential of ADCs for the treatment of NSCLC
Understand recent clinical evidence for the use of ADC monotherapy versus combination approaches with other immunotherapies
Improve coordination and communication within the multidisciplinary cancer care team to optimize outcomes for patients with NSCLC being treated with ADCs
Review patient selection principles and implications of treatment selection for future therapeutic options in NSCLC.

Provided by Association of Cancer Care Centers.

This activity is supported by an educational grant from AstraZeneca.

Benjamin P. Levy, MD

Clinical Director of Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital

Beth Sandy, CRNP

Thoracic Oncology Nurse Practitioner, Abramson Cancer Center, University of Pennsylvania

Alexander Spira MD, PhD, FACP, FASCO

Co-Director, VCS Research Institute, Director, Thoracic and Phase I Program, Clinical Assistant Professor, Johns Hopkins School of Medicine